Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 11/20 | 0.64 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.62 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.62 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.61 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.61 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.56 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13196399 | 0.92 | ADRA2A (0.71) | ADRA2AADRA2BADRA2CCYP19A1CYP11B2 | |
| SCHEMBL7944637 | 0.76 | CYP11B2 (1.00) | ADRA2AADRA2BADRA2CCYP19A1CYP11B2 | |
| SCHEMBL4204524 | 0.72 | ADRA1A (0.59) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL31140107 | 0.72 | ADRA2A (0.64) | ADRA2AADRA2BADRA2CCYP19A1CYP11B2 | |
| SCHEMBL31140093 | 0.72 | ADRA2A (0.60) | ADRA2AADRA2BADRA2CCYP19A1CYP11B2 | |
| SCHEMBL769064 | 0.72 | ADRA2A (0.67) | ADRA2AADRA2BADRA2CCYP19A1CYP11B2 | |
| SCHEMBL31140124 | 0.72 | ADRA2A (0.74) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL20874477 | 0.71 | GID4 (0.56) | ADRA2ACYP19A1CYP11B2ADRA1DADRA1A | |
| SCHEMBL3668028 | 0.71 | ADRA2A (0.54) | ADRA2AADRA1DADRA1AADRA1B | |
| SCHEMBL769063 | 0.71 | ADRA1A (0.55) | ADRA2AADRA2BADRA2CADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12414937-B2 | Local and regional anesthesia and analgesia | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2025-09-16 | — | — | US | claimed |
| EP-3370718-B1 | LOCAL AND REGIONAL ANESTHESIA AND ANALGESIA | UNIV LOUISVILLE RES FOUND INC (US) | 2021-01-27 | — | — | EP | claimed |
| US-20200383953-A1 | LOCAL AND REGIONAL ANESTHESIA AND ANALGESIA | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. | 2020-12-10 | — | — | US | claimed |
| EP-3370718-A1 | LOCAL AND REGIONAL ANESTHESIA AND ANALGESIA | University Of Louisville Research Foundation, Inc. (US) | 2018-09-12 | — | — | EP | claimed |
| WO-2017079734-A1 | LOCAL AND REGIONAL ANESTHESIA AND ANALGESIA | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2017-05-11 | — | — | WO | claimed |
| EP-3370718-B1 | LOCAL AND REGIONAL ANESTHESIA AND ANALGESIA | UNIV LOUISVILLE RES FOUND INC (US) | 2021-01-27 | — | — | EP | disclosed |
| EP-3370718-B1 | LOCAL AND REGIONAL ANESTHESIA AND ANALGESIA | UNIV LOUISVILLE RES FOUND INC (US) | 2021-01-27 | — | — | EP | disclosed |
| US-20200383953-A1 | LOCAL AND REGIONAL ANESTHESIA AND ANALGESIA | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. | 2020-12-10 | — | — | US | disclosed |
| US-20120071506-A1 | METHODS FOR TREATING CNS DISORDERS WITH BICYCLO-SUBSTITUTED 2-IMIDAZOLINE AND 2-IMIDAZOLES | GALLEY GUIDO (DE) | 2012-03-22 | — | — | US | disclosed |
| US-20120071506-A1 | METHODS FOR TREATING CNS DISORDERS WITH BICYCLO-SUBSTITUTED 2-IMIDAZOLINE AND 2-IMIDAZOLES | GALLEY GUIDO (DE) | 2012-03-22 | — | — | US | disclosed |
| US-20070197620-A1 | Methods for treating CNS disorders with bicyclo-substituted 2-imidazoline and 2-imidazoles | HOFFMANN-LA ROCHE INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070197620-A1 | Methods for treating CNS disorders with bicyclo-substituted 2-imidazoline and 2-imidazoles | HOFFMANN-LA ROCHE INC. | 2007-08-23 | — | — | US | disclosed |
| WO-2007085558-A1 | USE OF 2-IMIDAZOLES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071506-A1 | METHODS FOR TREATING CNS DISORDERS WITH BICYCLO-SUBSTITUTED 2-IMIDAZOLINE AND 2-IMIDAZOLES | CRY1, PER2, GPR119 | ADRA2A 102/4885ADRA2B 134/4885ADRA2C 38/4885 |
| US-20200383953-A1 | LOCAL AND REGIONAL ANESTHESIA AND ANALGESIA | OPRL1, OPRK1, OPRM1 | ADRA2A 5/4885ADRA2B 8/4885ADRA2C 4/4885 |
| US-20070197620-A1 | Methods for treating CNS disorders with bicyclo-substituted 2-imidazoline and 2-imidazoles | CRY1, PER2, GPR119 | ADRA2A 106/4885ADRA2B 125/4885ADRA2C 37/4885 |
| US-12414937-B2 | Local and regional anesthesia and analgesia | OPRL1, OPRK1, OPRM1 | ADRA2A 5/4885ADRA2B 8/4885ADRA2C 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.